5-Hydroxymethylcytosine Profiling of Cell-Free DNA Disease Detection in High-Risk Relapsed or Refractory Neuroblastoma
We evaluated the utility of cell-free DNA (cfDNA) 5-hydroxymethylcytosine (5hmC) profiling as a minimally invasive approach to monitor disease burden in pediatric patients with relapsed or refractory high-risk neuroblastoma. Plasma samples were collected from children enrolled on NANT consortium biology study (NANT 2004-05) and NANT 2015-01 study (NCT02868268). Nano-hmC-Seal sequencing was performed on cfDNA extracted from plasma to generate whole-genome 5hmC profiles, yielding a total of 59 samples from 38 patients passed sequencing quality control. A previously validated 450-gene based neuroblastoma score (NBL score) derived from 5hmC enrichment patterns was compared against a TaqMan Low-Density Array (TLDA)-based assay quantifying circulating mRNA levels of five neuroblastoma-specific genes, using matched peripheral blood samples. Performance of each assay was assessed against clinical disease burden measures including Curie score and bone marrow tumor involvement, as well as patient survival outcomes. Whole-genome 5hMC sequencing data (FASTQ) generated from patient plasma cfDNA will be made available through dbGaP.
- Type: Cohort
- Archive: The database of Genotypes and Phenotypes (dbGaP)
